Evgen Pharma has announced a new collaboration with the Universita Sapienza di Roma to investigate the potential radiosensitisation effects of Evgen’s lead cancer drug SFX-01. SFX-01 is the anti-cancer drug sulforaphane stabilised using Evgen’s Suforadex technology platform. SFX-01 has already completed a phase II open label study in the treatment of metastatic breast cancer and is being evaluated in the brain cancer glioblastoma, which is due to commence a Phase II study in H2 2022 (where in th ....
26 May 2022
Evgen Pharma - New SFX-01 collaboration
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Evgen Pharma - New SFX-01 collaboration
Evgen Pharma Plc (EVG:LON) | 0.8 0 0.0% | Mkt Cap: 3.42m
- Published:
26 May 2022 -
Author:
Mark Brewer | Cavendish Research -
Pages:
7
Evgen Pharma has announced a new collaboration with the Universita Sapienza di Roma to investigate the potential radiosensitisation effects of Evgen’s lead cancer drug SFX-01. SFX-01 is the anti-cancer drug sulforaphane stabilised using Evgen’s Suforadex technology platform. SFX-01 has already completed a phase II open label study in the treatment of metastatic breast cancer and is being evaluated in the brain cancer glioblastoma, which is due to commence a Phase II study in H2 2022 (where in th ....